Table A9.

HPV-FRAME reporting standards for models of cervical screening.^∗

Inputs	Reported? (Y/N)	Report by age? (Y/N)	Comment∗∗
Routine screening behaviour (routine and follow-up and test-of-cure)	Y	Y	Screening age-group, percentage of women who are never screened, and percentage of women not screened. Clinician-collected vs self-collected sample Organisation of screening (opportunistic vs programmatic) Proportion attending (or rate) screening for each age group at specified interval cycles (on-time screening) Proportion attending (or rate) screening beyond screening intervals i.e. over-screening (important for costs)
Screening test(s) and colposcopy accuracies	Y	N	Report by test result: cytology grade for cytology or HPV type for HPV tests; report on sensitivity and specificity or equivalent specification if test accuracy. Proportion unsatisfactory tests
Abnormal test management (primary and triage)	Y	N	Distinction of result grade (e.g. cytology grade). Separate management by test result Sensitivity and specificity values of cytology or other test result
Diagnostic follow-up of abnormal tests	Y	N	Indication of diagnostic follow-up Distinct colposcopy and biopsy outcomes
			Sensitivity and specificity values of colposcopy
Management by disease grade (confirmed disease)	Y	N	Indication of HSIL management Distinct HSIL management approaches Treatment efficacy of treated HSIL
			Follow-up of treated disease
Sources of information for screening structure and parameterization	Y	N	Guidelines Survey or surveillance Expert opinion/personal communication
			Assumption

Abbreviations: HSIL: high grade squamous intraepithelial neoplasia

^∗HPV-FRAME core reporting standards are also applicable.

^∗∗Each reporting standard should encompass both primary and secondary tests, where relevant.